These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33901792)

  • 21. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerling R; Kirchner T; Jung A; Folwaczny M; Yang D; Ning Y; Sebio A; Stremitzer S; Sunakawa Y; Matsusaka S; Yamauchi S; Loupakis F; Cremolini C; Falcone A; Lenz HJ
    Mol Cancer Ther; 2015 Oct; 14(10):2374-81. PubMed ID: 26206335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    Modest DP; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Scheithauer W; Moehler M; Westphalen CB; Holch JW; von Einem JC; Held S; Heinemann V;
    Eur J Cancer; 2017 Oct; 84():262-269. PubMed ID: 28843184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
    Bang YH; Hong YS; Lee JS; Lee KW; Han HS; Kim SY; Kim JW; Kim HK; Kim JW; Eun CK; Kim TW; Kim JE
    Clin Colorectal Cancer; 2021 Jun; 20(2):101-112.e6. PubMed ID: 33223477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
    Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
    Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials.
    Wang J; Millstein J; Yang Y; Stintzing S; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Mancao C; Cremolini C; Liu T; Heinemann V; Falcone A; Shen L; Lenz HJ
    EClinicalMedicine; 2023 Mar; 57():101827. PubMed ID: 36816347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
    Hsu HC; Liu YC; Wang CW; Chou WC; Hsu YJ; Chiang JM; Lin YC; Yang TS
    Cancer Med; 2019 Jul; 8(7):3437-3446. PubMed ID: 31090176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
    Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
    Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
    Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
    Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
    Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
    J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Arai H; Xiao Y; Millstein J; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Parikh AR; Lenz HJ
    Br J Cancer; 2022 Jan; 126(1):72-78. PubMed ID: 34689170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.